Beovu

Beovu is a prescription medicine given by injection into the eye. It is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).

Vascular endothelial growth factor (VEGF) is a protein responsible for producing new blood vessels. An excess amount of VEGF results in abnormal blood vessel growth. Beovu blocks VEGF. This can help slow the growth of abnormal blood vessels that leak fluid into the macula, the portion of eye at the center of the retina that processes sharp, clear, straight-ahead vision.

Beovu is given by monthly injection into the eye for the first 3 treatments. Thereafter, Beovu is given once every 2-3 months.

The most common side effects reported are reduced clarity in vision, cataract, broken blood vessels in the eye, and vitreous floaters (moving spots in the field of vision). You may experience temporary visual disturbances after an injection with Beovu. Do not to drive or use machinery until your vision has returned to normal.

Beovu is a prescription medication used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).

This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.

Serious side effects have been reported with Beovu. See the "Beovu Precautions" section.

Common side effects of Beovu include reduced clarity in vision, cataract, broken blood vessels in the eye, and vitreous floaters (moving spots in the field of vision).

This is not a complete list of Beovu side effects. Ask your doctor or pharmacist for more information.

Tell your doctor if you have any side effect that bothers you or does not go away.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

No drug interactions have been studied by the manufacturer. However, you should tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Not all drug interactions are known or reported and new drug interactions are continually being reported.

You should not use Beovu if you have an infection in or around the eye, eye inflammation, or if you are allergic to brolucizumab or any of the ingredients in Beovu.

Endophthalmitis and Retinal Detachments. Beovu is a prescription medicine given by injection into the eye. Injections in the eye, including Beovu, may cause an infection of the eye or retinal detachment (separation of retina from the back of the eye). It is important to contact your doctor right away if your eye becomes red, sensitive to light, painful, or you develop a change in your vision.

Increase in Intraocular Pressure. Increased eye pressure has been seen within 30 minutes of an eye injection, including Beovu. Sustained increases in eye pressure also have been reported. Your doctor should monitor for this when you receive a Beovu injection.

Thromboembolic Events. There is a potential risk of stroke, heart attack, or blood clots in patients receiving eye injections of vascular endothelial growth factor (VEGF) inhibitor drugs, including Beovu.

Medications can interact with certain foods. In some cases, this may be harmful and your doctor may advise you to avoid certain foods. In the case of Beovu, there are no specific foods that you must exclude from your diet when receiving this medication.

Before taking Beovu, tell your doctor about all of your medical conditions. Especially tell your doctor if you:

• are allergic to brolucizumab or any of the ingredients in Beovu
• have an infection in or around the eye, or if you have eye inflammation
• are pregnant or plan to become pregnant
• are breastfeeding or plan to breastfeed

Tell your doctor about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements.

Tell your doctor if you are pregnant or plan to become pregnant.

There are no well-done studies that have been done in humans with Beovu. In animal studies, pregnant animals were given a VEGF inhibitor and the babies showed medical issues related to this medication including malformations, embryo-fetal resorption, and decreased fetal weight. Therefore, this medication may be used if the potential benefits to the mother outweigh the potential risks to the unborn child.

Tell your doctor if you are breastfeeding or plan to breastfeed.

It is not known if Beovu crosses into human milk. Because many medications can cross into human milk and because the possibility for serious adverse reactions in nursing infants with use of this medication, a choice should be made whether to stop nursing or stop the use of this medication. Your doctor and you will decide if the benefits outweigh the risk of using Beovu.

Beovu is administered by intravitreal injection. This means that the medication will be injected into the eye with a small needle.

The procedure is done in your provider's office. It takes about 15 to 30 minutes.

• Drops will be placed in your eyes to widen (dilate) the pupils.
• You will lie face up in a comfortable position.
• Your eyes and eyelids will be cleaned.
• Numbing drops will be placed in your eye.
• A small device will keep your eyelids open during the procedure.
• You will be asked to look toward the other eye.
• Medicine will be injected into your eye with a small needle. You may feel pressure, but not pain.
• Antibiotic drops may be placed in your eye.

The recommended dose for Beovu is 6 mg received by monthly injection for the first 3 treatments. Thereafter, Beovu is given once every 2-3 months.

Beovu is usually administered by a healthcare provider in a medical setting making it unlikely for an overdose to occur. However, if overdose is suspected, seek emergency medical attention.

Beovu is stored under refrigeration at temperatures between 2 to 8°C (36 to 46°F). Do not freeze. Store the vial in the outer carton to protect from light.